Skip to content
Bored Studies
RecruitingPhase 2

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

AbbVie · NCT06846320

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–65 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
315
US sites recruiting
47
Study start
April 29, 2025
Record last updated
June 17, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs.

ABBV-932 is an investigational drug being developed for the adjunctive treatment of GAD. Participants will be randomly assigned to receive ABBV-932 or Placebo in addition to their currently prescribed ADTs. There is 1 in 3 chance of participants assigned to Placebo. Approximately 315 adult participants with GAD and inadequate response to ADTs will be enrolled in approximately 50 sites in the United States and Puerto Rico.

Participants will receive oral capsules of ABBV-932 or matching placebo in addition to their prescribed ADT for 6 weeks and then will be followed for an additional 4 week follow-up period.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Being studied: ABBV-932; Placebo for ABBV-932; Antidepressant Therapy (ADT)

Conditions: Generalized Anxiety Disorder (GAD)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for generalized anxiety disorder (GAD) confirmed by the Mini International Neuropsychiatric Interview (MINI).
  • Currently taking protocol-specified antidepressant therapies (ADT) for GAD with an inadequate response to an adequate dose (per label) and duration (>= 8 weeks) as verified by a baseline Hamilton Anxiety Rating Scale (HAM-A) total score >= 20 and Clinical Global Impression of Severity Scale (CGI-S GAD) >= 4.

Exclusion Criteria

  • Have a Montgomery-Åsberg Depression Rating Scale (MADRS) score >= 20.
  • New diagnosis or exacerbation of major depression in the last 6 months.

Recruiting US locations

  • University of Alabama - Huntsville Regional Medical Campus /ID# 267818

    Huntsville, AL 35801

    Site contact: Site Coordinator · 256-551-4431

  • Ima Clinical Research Phoenix (Alea) /ID# 275737

    Phoenix, AZ 85012

  • Advanced Research Center /ID# 267874

    Anaheim, CA 92805

    Site contact: Site Coordinator · 714-999-6688

  • Axiom Research /ID# 267814

    Colton, CA 92324

    Site contact: Site Coordinator · 909-824-2325

  • Sun Valley Research Center /ID# 267864

    Imperial, CA 92251

    Site contact: Site Coordinator · 760-545-0123

  • Synergy San Diego /ID# 267879

    Lemon Grove, CA 91945

  • Alliance for Research Alliance for Wellness /ID# 267911

    Long Beach, CA 90807

  • NRC Research Institute DTLA /ID# 267832

    Los Angeles, CA 90015

    Site contact: Site Coordinator · 714-289-1100

  • Excell Research /ID# 267918

    Oceanside, CA 92056

  • Inland Psychiatric Medical Group /ID# 268598

    Temecula, CA 92591

  • Sunwise Clinical Research /ID# 267863

    Walnut Creek, CA 94596

    Site contact: Site Coordinator · 925-298-5147

  • Connecticut Clinical Research - Cromwell /ID# 271241

    Cromwell, CT 06416

  • Cns Healthcare - Jacksonville /ID# 268588

    Jacksonville, FL 32256

  • Accel Research Sites Network - St. Pete /ID# 267821

    Largo, FL 33777

    Site contact: Site Coordinator · 321-878-9477

  • K2 Medical Research, LLC /ID# 267841

    Maitland, FL 32751

  • GMI Florida - Central Miami Medical Institute /ID# 267839

    Miami, FL 33125

    Site contact: Site Coordinator · 305-547-2011

  • Allied Biomedical Res Inst Inc /ID# 267813

    Miami, FL 33155

    Site contact: Site Coordinator · 305-643-8400

  • Apg Research /ID# 271707

    Orlando, FL 32803

  • Psych Atlanta /ID# 267878

    Marietta, GA 30060

  • iResearch Savannah /ID# 267865

    Savannah, GA 31405

    Site contact: Site Coordinator · 912-744-0800

  • University of Chicago Medical Center /ID# 275131

    Chicago, IL 60637

  • Collective Medical Research /ID# 272015

    Overland Park, KS 66210

  • CenExel /ID# 267853

    Gaithersburg, MD 20877-1407

    Site contact: Site Coordinator · 301-251-4702

  • Elixia - Springfield /ID# 267815

    Springfield, MA 01103

  • Psychiatric Care And Research Center /ID# 271701

    O'Fallon, MO 63368

  • Saint Charles Psychiatric Associates /ID# 271202

    Saint Charles, MO 63304

  • Arch Clinical Trials /ID# 267851

    St Louis, MO 63125

  • Ima Clinical Research Las Vegas (SMO/Network/Consortium) /ID# 275731

    Las Vegas, NV 89102

  • Princeton Medical Institute /ID# 267877

    Princeton, NJ 08540

    Site contact: Site Coordinator · 609-921-3555

  • Bio Behavioral Health /ID# 267919

    Toms River, NJ 08755

  • Integrative Clinical Trials /ID# 279519

    Brooklyn, NY 11229

  • New Hope Clinical Research - Inpatient unit /ID# 267810

    Charlotte, NC 28211

    Site contact: Site Coordinator · 980-209-9784

  • Quest Therapeutics of Avon /ID# 267829

    Avon Lake, OH 44012-1004

    Site contact: Site Coordinator · 440-949-9115

  • University Of Cincinnati Medical Center /ID# 271704

    Cincinnati, OH 45219

  • The Ohio State University /ID# 267924

    Columbus, OH 43210

  • Sooner Clinical Research /ID# 267881

    Oklahoma City, OK 73116

  • Lehigh Center for Clinical Research /ID# 267908

    Allentown, PA 18103

  • Suburban Research Associates /ID# 267868

    West Chester, PA 19380-4370

    Site contact: Site Coordinator · 610-891-7200

  • Coastal Carolina Research Center, LLC /ID# 267826

    Charleston, SC 29492

    Site contact: Site Coordinator · 321-878-9477

  • Psychiatric Consultants - Franklin /ID# 275133

    Franklin, TN 37067

    Site contact: Site Coordinator · 615-807-4023

  • FutureSearch Trials of Dallas /ID# 267870

    Dallas, TX 75231

  • Relaro Medical Trials /ID# 270241

    Dallas, TX 75243

  • Perceptive Pharma Research /ID# 267836

    Richmond, TX 77407

    Site contact: Site Coordinator · 346-467-2182

  • Family Psychiatry Of The Woodlands /ID# 275173

    The Woodlands, TX 77381

  • Grayline Research Center /ID# 267811

    Wichita Falls, TX 76309

    Site contact: Site Coordinator · 940-322-1131

  • Northwest Clinical Research Center /ID# 267916

    Bellevue, WA 98007

  • Core Clinical Research /ID# 270058

    Everett, WA 98201

Study contacts (from the official record)

  • ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
All mental health studies in Alabama →
Study to Assess Adverse Events and Change in Disease Activity When… (NCT06846320) | Bored Studies